Autoimmune diagnosis market seen rising to $9.38 billion by 2030

The autoimmune disease diagnosis market is projected to climb from $6.2 billion in 2025 to $6.74 billion in 2026, with further growth expected through 2030. The Business Research Company says rising autoimmune prevalence, higher healthcare spending and new testing technologies are expanding demand for faster, more precise diagnosis.

Why it matters: - Autoimmune disease diagnosis is becoming more important as more patients need earlier and more accurate identification of complex immune disorders. - The market’s growth signals rising demand for immunological testing, laboratory capacity and point-of-care diagnostics. - Better diagnosis can speed treatment decisions and help slow disease progression.

What happened: - The Business Research Company published its Autoimmune Disease Diagnosis Global Market Report 2026, covering market size, trends and forecasts through 2035. - The report estimates the market will rise from $6.2 billion in 2025 to $6.74 billion in 2026. - The report forecasts the market will reach $9.38 billion by 2030. - North America held the largest regional share in 2025. - Western Europe ranked second, while the analysis also covers Asia-Pacific, South East Asia, Eastern Europe, South America, the Middle East and Africa. - A free sample of the report is available here. - The full report is available here.

The details: - The report says market growth is being driven by rising prevalence of autoimmune disorders, broader access to immunoassay technologies, growth in clinical laboratory networks, greater physician awareness and more routine screening. - The report ties future growth to demand for early and precise diagnosis, AI-assisted diagnostic tools, personalized diagnostics, expanded research funding and point-of-care testing. - Expected product and workflow changes include more advanced immunological tests, autoantibody panels, multiplex diagnostic platforms and greater laboratory automation. - Autoimmune disease diagnosis covers conditions where the immune system attacks healthy cells. - The report lists Crohn's disease, rheumatoid arthritis, Hashimoto’s disease, multiple sclerosis, Grave’s disease, psoriasis, coeliac disease, type 1 diabetes, lupus and inflammatory bowel syndrome among the conditions in scope. - Immunological testing is used to detect abnormal antibody production and immune responses. - The report says accurate diagnosis supports tailored treatment plans and better disease management. - Rising autoimmune disease incidence is a major market driver, with environmental factors such as pollution, infections and lifestyle changes contributing to immune disruption. - In March 2023, the Society for Women’s Health Research said the number of people affected by autoimmune diseases ranges from 23.5 million to 50 million. - The same source said global prevalence is rising by 3% to 9% annually. - Higher healthcare spending is also supporting market growth by improving access to medical services and diagnostic capability. - In May 2024, the UK Office for National Statistics reported a 5.6% nominal increase in total healthcare expenditure from 2022 to 2023, up from 0.9% growth in the prior year. - The report’s 2026 package includes market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technology analysis and updated graphics and tables.

Between the lines: - The forecast points to a market moving from basic detection toward faster, more integrated diagnostic workflows. - The emphasis on AI, multiplex platforms and automation suggests laboratories are under pressure to handle more testing with greater precision. - North America’s lead indicates the region remains the most developed market for diagnostic adoption, while other regions may offer room for expansion.

What's next: - The report expects continued expansion through 2030 as early detection, specialized assays and new digital tools gain traction. - Wider use of point-of-care testing and laboratory automation is likely to shape purchasing and product development decisions. - Growth opportunities may track with rising healthcare budgets and broader awareness of autoimmune disease symptoms and testing options.